Overall serious adverse events of grade 3–5 were noted in four (13.8%) patients in which pneumonitis were noted in two (6.9%) patients, skin rash in one (3.4%) patient and elevated AST/ALT in one (3.4%) patient. The gene discussed is GPT; the disease is pneumonitis.